Anticoagulation and ACS Practice Test 2026 - Free Anticoagulation and ACS Practice Questions and Study Guide

In unprovoked VTE, the risk of recurrence remains substantial after stopping therapy. If the bleeding risk is low to moderate, continuing anticoagulation beyond the initial 3 months is favored because it markedly lowers the chance of another clot, and DOACs offer a favorable balance of efficacy and safety compared with warfarin. DOACs provide strong protection against recurrence without the need for regular INR monitoring and generally have a lower risk of intracranial bleeding. Guidelines and trials support ongoing DOAC therapy beyond 3 months in patients with low to moderate bleeding risk, including extended or even indefinite treatment for some. There’s no requirement to switch to warfarin or to wait a fixed lengthy period like 5 years.